Internship

Intern

Biostatistics

Posted on 11/1/2024

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Cambridge, MA, USA

70% in-office work model.

Category
Computational Biology
Public Health
Biology & Biotech
Required Skills
Python
Data Science
R
AWS
Perl
Google Cloud Platform
Requirements
  • PhD student or Master Student in statistics, biostatistics, computational biology, statistical genetics, data science or related disciplines.
  • Excellent statistical knowledge and quantitative skill with the ability of applying the knowledge to solve scientific and clinical problems.
  • Experience in R, AWS/GCP, and at least one programming language (e.g. Python or Perl) is essential.
  • Experience with handling high dimensional data and create visualization apps.
  • Outstanding communication skills (verbal and written).
Responsibilities
  • Collaborate with scientists and statistical programmers to solve challenge data related problems in clinical studies and harmonize various data using clinical data standard.
  • Build tools and pipelines for both scientists and statisticians to drive business solutions in a data driven way.
  • Champion in bringing state-of-art statistical thinking and methods to help drive applications of suit-for-purpose statistical methods and visualizations that enhance the probability of successes for clinical development programs.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a molecule that provides instructions for cells to produce proteins essential for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially enhance the discovery, development, and manufacturing of drugs. Unlike traditional methods, which often rely on proteins or other biological materials, Moderna's use of mRNA allows for a more direct and efficient way to instruct cells to produce therapeutic proteins. The company's goal is to improve patient outcomes by harnessing the power of mRNA technology to create effective treatments for a range of diseases.

Company Stage

IPO

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

3%

1 year growth

15%

2 year growth

53%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's expansion into combination vaccines and autoimmune therapies showcases its potential for diversified revenue streams and market leadership.
  • The company's continuous innovation and FDA approvals for updated COVID-19 vaccines highlight its resilience and adaptability in a rapidly changing market.
  • Moderna's educational initiatives, like the free mRNA course, position it as a thought leader and advocate for mRNA technology.

What critics are saying

  • The collapse in demand for COVID-19 vaccines could significantly impact Moderna's revenue and growth prospects.
  • Ongoing class action lawsuits alleging securities fraud could damage Moderna's reputation and financial stability.

What makes Moderna unique

  • Moderna is pioneering the use of mRNA technology to create a new class of medicines, setting it apart from traditional pharmaceutical companies.
  • The company's focus on mRNA as the 'software of life' allows for rapid development and manufacturing of vaccines and therapies, unlike conventional methods.
  • Moderna's ability to secure regulatory approvals for mRNA vaccines beyond COVID-19, such as for RSV, demonstrates its leadership in mRNA technology.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE